Mostrar el registro sencillo del ítem

Artículo

dc.creatorFontserè, Saraes
dc.creatorInfante Domínguez, María del Carmenes
dc.creatorSuárez-Benjumea, Alejandroes
dc.creatorSuñer-Poblet, Martaes
dc.creatorGonzález-Corvillo, Carmenes
dc.creatorMartín Gutiérrez, Guillermoes
dc.creatorBernal, Gabrieles
dc.creatorPachón Díaz, Jerónimoes
dc.creatorPachón Ibáñez, María Eugeniaes
dc.creatorCordero Matia, María Elisaes
dc.date.accessioned2021-05-21T08:01:17Z
dc.date.available2021-05-21T08:01:17Z
dc.date.issued2021-02-22
dc.identifier.citationFontserè, S., Infante Domínguez, M.d.C., Suárez-Benjumea, A., Suñer-Poblet, M., González-Corvillo, C., Martín-Gutiérrez, G.,...,Cordero Matia, M.E. (2021). Impact of treating asymptomatic bacteriuria in kidney transplant recipients: a prospective cohort study. Antibiotics, 10 (2)
dc.identifier.issn2079-6382(electrónico)es
dc.identifier.urihttps://hdl.handle.net/11441/109148
dc.description.abstractThis study aims to define the epidemiologic, clinical, and microbiological features of asymptomatic bacteriuria (AB) and cystitis in kidney transplantation recipients (KTRs), and to determine the impact of antimicrobial therapy of AB and the risk factors of cystitis. We conducted a prospective observational study of AB and cystitis in KTRs from January to June 2017. One-hundred ninety seven KTRs were included: 175 (88.8%) with AB and 22 (11.2%) with cystitis. The most frequent etiologies were Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Pseudomonas aeruginosa. No differences were observed regarding the etiologies, antimicrobial susceptibility patterns, and microbiologic outcomes in AB vs. cystitis. The treatment of AB diminished the microbiological cure and increased the rates of microbiologic relapses and reinfections; in addition, treated AB patients showed a trend of developing symptomatic urinary tract infection in the following six months. The analysis of the data identified the following independent risk factors for cystitis during the six months of follow-up: AB treatment, thymoglobulin induction, previous acute pyelonephritis, and time since transplantation < 1 year. In summary, considering the lack of clinical benefits of treating AB and its impact on cystitis development in the follow-up, we support the recommendation of not screening for or treating AB.es
dc.description.sponsorshipInstituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación, Ministerio de Economía, Industria y Competitividad PI17-01405es
dc.description.sponsorshipPlan Nacional de I + D + i 2013-2016es
dc.description.sponsorshipInstituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Red Española de Investigación en Enfermedades Infecciosas REIPI RD16 / 0016/0009es
dc.description.sponsorshipCofinanciada por el Fondo Regional de Desarrollo Europeo 2014-2020. G.M.-G.es
dc.description.sponsorshipContrato de Acceso al Sistema Español de Investigación e Innovación, V Programa de Investigación de la Universidad de Sevilla USE13901-Des
dc.formatapplication/pdfes
dc.format.extent11es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofAntibiotics, 10 (2)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectUrinary tract infectionses
dc.subjectKidney recipientses
dc.subjectAsymptomatic bacteriuriaes
dc.subjectCystitises
dc.subjectProspective observational cohortes
dc.titleImpact of treating asymptomatic bacteriuria in kidney transplant recipients: a prospective cohort studyes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDPI17-01405es
dc.relation.projectIDI + D + i 2013-2016es
dc.relation.projectIDREIPI RD16 / 0016/0009es
dc.relation.projectID2014-2020. G.M.-G.es
dc.relation.projectIDUSE13901-Des
dc.relation.publisherversionhttps://doi.org/10.3390/antibiotics10020218es
dc.identifier.doi10.3390/antibiotics10020218es
dc.journaltitleAntibioticses
dc.publication.volumen10es
dc.publication.issue2es

FicherosTamañoFormatoVerDescripción
Impact of treating asymptomatic ...280.3KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional